5-HT2A Receptor Agonists for Drug-Resistant Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychiatric conditions, particularly depression and anxiety, often rely on selective serotonin reuptake inhibitors that are no more effective than placebos in mild and moderate cases, and there is a lack of understanding of the neurobiological effects of psychedelic-assisted psychotherapy, limiting the development of more potent and selective 5-HT2AR agonists.
Innovation Solution
Development of 15 novel ligands (TTA005 to TTA039) that act as selective and potent agonists of the 5-HT2A receptor, which can be administered as therapeutically effective compositions to treat mental disorders such as depression and anxiety, with a focus on providing a better-defined molecular mode of action and potential for long-lasting therapeutic effects without inducing a psychedelic state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current selective serotonin reuptake inhibitors are used for treating psychiatric conditions, then treatment is provided, but efficacy is little better than placebo in mild and moderate cases
Solution Approach 1:
The patent applies parameter changes by developing novel ligands with modified chemical structures (TTA005-TTA039) that have improved binding affinities to the 5-HT2A receptor compared to existing psychedelics. This involves changing molecular parameters such as substitution patterns on the indole ring and amine group configurations to optimize receptor interaction and therapeutic efficacy while reducing off-target effects
2Reliability
If psychedelic-assisted psychotherapy is used, then therapeutic effects are achieved, but the molecular mode of action is not well understood
Solution Approach 1:
The patent employs structure-based modeling and computational methods to create detailed copies and representations of ligand-receptor interactions. By using the available 5-HT2A receptor crystal structures and performing molecular docking simulations, the researchers can visualize and analyze the precise molecular mode of action without requiring direct experimental observation of neural circuits in human patients
3Reliability
If existing psychedelic ligands are used, then 5-HT2A receptor activation occurs, but selectivity and potency are limited
Solution Approach 1:
The patent applies local quality by introducing specific substitutions at particular positions on the psychedelic molecule framework. For example, adding fluorine atoms at specific ring positions or modifying the amine substituent groups creates localized changes in electron distribution and steric properties that enhance binding affinity to specific amino acid residues in the 5-HT2A receptor binding pocket while maintaining overall molecular architecture
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types (fluorine, methyl, hydroxyl groups), substituent positions (2-, 3-, 4-positions on indole ring), and chain lengths to optimize the balance between potency and selectivity for the 5-HT2A receptor compared to other serotonin receptor subtypes
4Adaptability or versatility
If multiple receptors are interacted with by psychedelics, then diverse effects are produced, but off-target effects increase
Solution Approach 1:
The patent extracts the specific pharmacophore features required for 5-HT2A receptor activation from the broader psychedelic molecule class. By identifying and preserving only the essential structural elements (the indole nucleus with specific substitution patterns and a basic amine group) while removing or modifying portions that contribute to off-target binding, the design achieves selective activation of the desired receptor subtype
Data Source
AI summary
Disclosed are a variety of structures for agonists of 5-HT2AR some of which show promise for activity greater than psilocin. The agonists of the present disclosure are expected to demonstrate therapeutic benefits to treat mental disorders. In some embodiments, the invention may comprise the use of the compounds of the present invention to treat depression, and particularly drug resistant depression. Other conditions that may be treated include: anxiety disorders, including anxiety in advanced stage illness e.g. cancer as well as generalized anxiety disorder, depression including major depressive disorder, postpartum depression, cluster headaches, obsessive compulsive disorder, personality disorders including conduct disorder, drug disorders including: alcohol dependence, nicotine dependence, opioid dependence, cocaine dependence and other addictions including gambling disorder, eating disorder and body dysmorphic disorder, chronic pain, or chronic fatigue.